General Motors (NYSE:GM): It appears as though bringing back the old nameplates Camaro and Mustang were not enough, since both GM and Ford Motor Co. (NYSE:F) have chosen to revitalize the Riviara and Escort badges too, both being unveiled at the Shanghai Motor Show this week. The Buick Riviera, a model that ran from 1963 to 1999, has been re-visioned as a flowing, plug-in hybrid that takes its cues from flowing water. The Escort is being pitched as a model that fits snugly between the compact Focus, and the larger Fusion.
Boeing Airlines (NYSE:BA): A day that the company has been anxiously awaiting since January has finally arrived: the Federal Aviation Administration has given the OK for the 787 Dreamliner’s battery fix, mean the ban put on the flight of the revolutionary aircraft will soon be lifted. Europe has too followed the FAA’s lead, and the airworthiness directive needed to resume flights is just around the corner for the Washington-based airplane maker.
ARCA Biopharma (NASDAQ:ABIO): Shares of ARCA are soaring almost 50 percent, following an announcement that the company will be collaborating with Medtronic (NYSE:MDT) for Phase II trials of Gencaro, ARCA’s lead developmental drug for the treatment of cardiac rhythm disorders. The new study will include continuous monitoring of the cardiac rhythms of all 200 patients enrolled during the Phase 2b portion, and each patient will have heart rhythm monitoring via a Medtronic device, the release said.
Delhaize Group (NYSE:DEG): Preliminary first quarter results pushed Delhaize’s shares up, following the announcement that said the Belgian food retailer’s revenues rose 2.1 percent, while comparable same-store sales growth in the U.S. grew 1.9 percent. Operating margins and EBITDA rose 0.4 percent and 7.1 percent year-over-year, respectively. The company sees operating profits of $1.01 billion for the full year.